Levetiracetam Terapia

Levetiracetam, the active ingredient in Levetiracetam Terapia, is an anticonvulsant presented as an oral tablet for oral administration. It is used to control partial‑onset, myoclonic, and generalized tonic‑clonic seizures in patients diagnosed with epilepsy.

GNH USA supplies Levetiracetam Terapia as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality‑assured products for diverse healthcare settings. The company adheres to stringent regulatory standards and provides reliable logistics, including temperature‑controlled shipping where required, to meet the needs of global procurement teams.

Levetiracetam is an anticonvulsant used to manage seizure disorders.

Partial‑onset seizures: decreases the number and severity of focal seizures by stabilizing neuronal firing in the affected brain region. Myoclonic seizures: lessens the frequency of sudden, brief muscle jerks, improving patient stability and daily functioning. Generalized tonic‑clonic seizures: reduces the occurrence of full‑body convulsions, helping to prevent injury and improve quality of life. Adjunctive therapy in epilepsy: employed alongside other antiepileptic drugs to achieve better seizure control.

Levetiracetam may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Dizziness: sensation of light‑headedness or unsteadiness. - Fatigue: persistent tiredness not relieved by rest. - Somnolence: increased sleepiness during daytime. - Headache: mild to moderate cranial pain. - Irritability: mood changes or increased agitation. - Nausea: feeling of stomach upset.

Serious or Rare Side Effects: - Severe allergic reactions: rash, swelling, or difficulty breathing. - Stevens‑Johnson syndrome: rare but life‑threatening skin disorder. - Suicidal thoughts: emergence of depressive or suicidal ideation. - Blood disorders: neutropenia or thrombocytopenia. - Multi‑organ hypersensitivity: systemic reaction affecting liver, kidneys, or lungs. - Severe skin rash: widespread erythema or blistering.

When prescribing levetiracetam, clinicians should consider several precautionary measures to ensure safe use.

Renal function: assess baseline renal status and monitor periodically. Hepatic disease: evaluate liver function before initiation. Psychiatric symptoms: observe for mood changes, depression, or aggression. Pregnancy: weigh potential risks against benefits and discuss with the patient. Concomitant CNS depressants: use caution as additive sedation may occur. Store at ambient temperature: keep below 25°C in the original container, protect from moisture and direct sunlight.

Levetiracetam can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Alcohol: may enhance central nervous system depression. - Carbamazepine: may lower levetiracetam plasma concentrations. - Strong enzyme inducers (e.g., phenytoin, phenobarbital): may decrease therapeutic effect.

Moderate Interactions (Monitor Closely): - Valproic acid: may increase levetiracetam levels, requiring observation. - Other antiepileptic drugs: combined use may necessitate dose adjustments. - Sedative agents (e.g., benzodiazepines): monitor for additive sedation.